Pent-up demand and a growing willingness to compromise on pricing are driving a healthcare deal rebound, private-equity dealmakers said at a recent investment conference focused on the sector. The value of North American healthcare buyouts this year through July 2 already surpassed the total for all of last year, supporting the bullish view. But heightened regulatory scrutiny tempered optimism, as lawmakers and rule enforcers have shaken up how the industry does business, raising the cost of negotiating some deals and extending the time it takes to get them done.
Read the full article: Private-Equity Healthcare Deals Rebound Despite Regulatory Scrutiny //
Source: https://www.wsj.com/articles/private-equity-healthcare-deals-rebound-despite-regulatory-scrutiny-268771df